TED Conversations

Rachel Lehmann-Haupt

Senior Editor, TED Books, TED Books

TEDCRED 20+

This conversation is closed.

How much of your information do you share? How much should corporations share? TED Books Q&A Friday at 3pm Eastern!

The way people connect and collaborate is undergoing an astonishing transformation. Smart organizations are shunning their old, secretive practices and embracing transparency. Companies are widely sharing intellectual property and releasing patents. And movements for freedom and justice are exploding everywhere.

In their new book, Radical Openness: Four Unexpected Principles for Success, authors Don Tapscott and Anthony D. Williams show how this revolutionary new philosophy is affecting every facet of our society, from the way we do business to whom we choose to govern us.

Buy and read the book:

Kindle: http://tinyurl.com/b99kw4m

Nook: http://tinyurl.com/ar9cz4r

iBookstore: http://tinyurl.com/ar9cz4r

Or download the TED Books app for your iPad or iPhone . (http://www.ted.com/pages/tedbooks) A subscription costs $4.99 a month, and is an all-you-can-read buffet.

Authors and TED Speakers Don Tapscott and Anthony Williams will be joining us soon for a one-hour live conversation, Friday 2/8 at 3pm Eastern!

Share:

Closing Statement from Rachel Lehmann-Haupt

Thanks everyone for joining the conversation - and especially thanks to Don and Anthony for such thoughtful answers to our questions and thoughts.

Showing single comment thread. View the full conversation.

  • Feb 8 2013: Re: your question about pharmaceuticals. In the past few years a lot of people have been talking about the crisis of innovation in drug development and arguing that the basic model for inventing and commercializing potentially life-saving medications is broken and failing society badly. The problems there have largely to do with a highly risk-averse and legalistic industry culture that comes at the expense of opportunities to co-develop early-stage technology tools, establish data standards, share clinical trial data or pursue other forms of collaboration that could lift the productivity of the entire industry. Fortunately, companies like GSK are strategically releasing patents and leading the charge toward more open models of drug development that will increase research productivity and stimulate medical progress.
    • Feb 8 2013: How is 'responsibility' from a legal perspective shifted under that model? If the problem is a risk-averse and legalistic operating culture, is this collaboration trying to share that responsibility across more shoulders, or is it trying to remove the burden entirely?

Showing single comment thread. View the full conversation.